News Search Results
Nov 06, 2025, 08:36 ET Arkstone's AI Clinical Decision Support Helps Treat Over 1 Million Patients
intelligence." About Arkstone Medical Solutions Arkstone is a biotechnology company providing clinical decision support powered by ML and AI, helping healthcare providers optimize antimicrobial use. Arkstone's OneChoice
More news about: Arkstone
Nov 06, 2025, 08:31 ET MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2025, and
More news about: MetaVia Inc.
Nov 06, 2025, 08:30 ET Using Early Real-world Evidence Generation to Drive Commercial Success, Upcoming Webinar with Sciensus, Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 06, 2025, 08:30 ET ALZpath Proprietary pTau217 Antibody Wins BioTech Breakthrough Award for 'Diagnostics Innovation of the Year'
BioTech Breakthrough, a leading independent market intelligence organization that honors excellence in the life sciences and biotechnology sectors. The award recognizes ALZpath's proprietary pTau217 antibody, which is driving earlier and more accessible detection and monitoring of Alzheimer's
More news about: ALZpath, Inc.
Nov 06, 2025, 08:30 ET Enhance Peptide Manufacturing Using Backbone N-Protecting Groups, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 06, 2025, 08:00 ET OncoHost Wins 'Proteomics Innovation of the Year' at the BioTech Breakthrough Awards
life sciences and biotechnology markets today. This year's program attracted thousands of nominations from over 15 different countries throughout the world, serving as a global recognition platform that encourages bold ideas and solutions that will shape the future of biotechnology.
More news about: OncoHost
Nov 06, 2025, 08:00 ET Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity
complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange
More news about: Palatin Technologies, Inc.
Nov 06, 2025, 07:34 ET Cannformatics to Announce Dementia and Medical Cannabis Study at the 2nd Annual New York State Medical Cannabis Symposium
Cannformatics Inc., a biotechnology company advancing the use of metabolic biomarkers and artificial intelligence to personalize medical cannabis treatment, today announced that a
More news about: Cannformatics
Nov 06, 2025, 07:30 ET Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering
complete clinical trials and submit applications for regulatory approvals; products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies; commercial acceptance of Palatin's products; and other factors discussed in Palatin's periodic filings with the SEC. All forward-looking
More news about: Palatin Technologies, Inc.
Nov 06, 2025, 07:27 ET MavriX Bio Announces First Patient Dosed in ASCEND-AS Trial of MVX-220, Investigational Gene Therapy for Angelman Syndrome
MIDDLETON, Mass., Nov. 6, 2025 /PRNewswire/ -- MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the first patient has been
More news about: AS2Bio
Nov 06, 2025, 07:22 ET Eilean Therapeutics to Present First-in-Class, Wild-Type-Sparing JAK2-JH2/V617F Inhibitor ZE74-0282 at ASH 2025 and Initiate Clinical Studies in December 2025
DOVER, Del., Nov. 6, 2025 /PRNewswire/ -- Eilean Therapeutics LLC, a biotechnology company developing next-generation precision medicines for cancer and immune-inflammatory diseases, today announced the upcoming presentation of
More news about: Eilean Therapeutics
Nov 06, 2025, 07:05 ET REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Nov 06, 2025, 07:04 ET Mwyngil Therapeutics Announces In-Licensing of GPR75 Modulators and Cell-Surface Discovery Platform from Expert Systems Inc.
About Mwyngil Therapeutics Mwyngil Therapeutics Inc. is a biotechnology company headquartered in Dover, Delaware, and Boston, Massachusetts, with research operations and partnering groups in Europe.
More news about: Mwyngil Therapeutics
Nov 06, 2025, 07:00 ET SkylineDx Wins 2025 BioTech Breakthrough Award for "Diagnostics Company of the Year"
and biotechnology companies, products, and services around the globe. The mission of the annual BioTech Breakthrough Awards program is to conduct the industry's most comprehensive analysis and evaluation of the world's top companies, solutions and products in the life sciences and biotechnology markets
More news about: SkylineDx
Nov 06, 2025, 07:00 ET NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board
/PRNewswire/ -- NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX" or the "Company"), a biotechnology company advancing transformative therapies for neurodegenerative and metabolic diseases, today announced that Professor Tamir Ben-Hur, MD, PhD,
More news about: NewcelX Ltd.
Nov 06, 2025, 06:45 ET Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Nov 06, 2025, 05:04 ET Proxima Clinical Research Acquired, Names Industry Veteran Eric Ross as new CEO to Drive Growth in Houston MedTech Hub
Headquartered within the Houston Texas Medical Center, the world's largest medical complex, Proxima partners with medical device, pharmaceutical, biotechnology, and diagnostic firms across 18 countries and five continents. Founded in 2017, Proxima operates as a registered Texas Corporation.
More news about: ProximaCRO
Nov 06, 2025, 03:00 ET Abzena and Mabqi Announce Strategic Partnership to Offer Integrated Discovery through Development Solution
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, and Mabqi, a biotechnology company focused on the discovery and development of fully human antibodies, announced the formation of a strategic partnership.
More news about: Abzena
Nov 05, 2025, 19:45 ET Evommune Announces Pricing of its Initial Public Offering
PALO ALTO, Calif., Nov. 5, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the pricing of its initial public
More news about: Evommune, Inc
Nov 05, 2025, 19:42 ET The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, announced that the first patient in its Investigator-Initiated
More news about: CorrectSequence Therapeutics
Nov 05, 2025, 19:00 ET The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, announced that the first patient in its Investigator-Initiated
More news about: CorrectSequence Therapeutics
Nov 05, 2025, 17:31 ET Rheumatoid Arthritis Market to Surge by 2034 as Next-Generation Biologics and JAK Inhibitors Gain Traction | DelveInsight
substantial; six of the world's top 50 bestselling drugs are currently used for rheumatoid arthritis treatment. Major pharmaceutical and biotechnology companies, including AbbVie, Amgen, Roche, Pfizer, Johnson & Johnson, and Bristol Myers Squibb, dominate the space. Many of these
More news about: DelveInsight Business Research, LLP
Nov 05, 2025, 16:05 ET Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
CARLSBAD, Calif., Nov. 5, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
Nov 05, 2025, 16:05 ET Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Nov 05, 2025, 16:00 ET Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, and Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that they have entered into
More news about: Dynavax Technologies